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Background: Expression levels of CD133, a cancer stem cell marker, and of the α-subunit of the dystroglycan
(α-DG) complex, have been previously reported to be altered in colorectal cancers.
Methods: Expression levels of CD133 and α-DG were assessed by immunohistochemistry in a series of colon
cancers and their prognostic significance was evaluated.
Results: Scattered cells positive for CD133 were rarely detected at the bases of the crypts in normal colonic
mucosa while in cancer cells the median percentage of positive cells was 5% (range 0–80). A significant correlation
was observed with pT parameter and tumor stage but not with tumor grade and N status. Recurrence and death
from disease were significantly more frequent in CD133-high expressing tumors and Kaplan-Meier curves showed a
significant separation between high vs low expressor groups for both disease-free (p = 0.002) and overall (p = 0.008)
survival.
Expression of α-DG was reduced in a significant fraction of tumors but low α-DG staining did not correlate with any
of the classical clinical-pathological parameters. Recurrence and death from the disease were significantly more
frequent in α-DG-low expressing tumors and Kaplan-Meier curves showed a significant separation between high vs
low expressor tumors for both disease-free (p = 0.02) and overall (p = 0.02) survival. Increased expression of CD133,
but not loss of α-DG, confirmed to be an independent prognostic parameters at a multivariate analysis associated
with an increased risk of recurrence (RR = 2.4; p = 0.002) and death (RR = 2.3; p = 0.003).
Conclusions: Loss of α-DG and increased CD133 expression are frequent events in human colon cancer and
evaluation of CD133 expression could help to identify high-risk colon cancer patients.
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The cancer stem cell (CSC) model of tumorigenesis pos-
tulates that only a small number of cancer cells are able
to both self renew and give rise to a differentiated pro-
geny. CSC are believed to be responsible for the primary
disease as well as its recurrence and metastasis. Thus,
it is expected that their evaluation in clinical samples
might provide useful information for a better prediction* Correspondence: asgambato@rm.unicatt.it
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reproduction in any medium, provided the orof disease aggressiveness and evolution. Although phe-
notypic characterisation of colon CSCs is still controver-
sial, CD133 is presently considered a useful marker to
identify CSC in colorectal cancers and its detection has
been used to evaluate the prognostic significance of CSC
in colon cancer patients [1-3].
Dystroglycan (DG) is a non-integrin adhesion molecule
expressed in a wide variety of tissues at the interface bet-
ween the basement membrane and the cell membrane [4].
It is formed by two subunits, the α (extracellular) and β
(transmembrane) subunits which bind to the major ECM
components and proteins involved in signal transductiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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implicated in several cell functions (i.e., growth control,
differentiation, shape change and movement) which are
all relevant in the process of tumour development and
metastasis [4-7]. We and others demonstrated that DG
expression, and mainly α-DG, is reduced or lost in a va-
riety of human cancer cell lines and primary tumours and
overall, the available findings indicate that loss of DG ex-
pression is a frequent event in human malignancies and
might play an important role in human tumour develop-
ment and progression [4-6,8-10].
In the present study, CD133 and DG expression levels
were analyzed by immunostaining in specimens of human
primary colon cancers from a large group of patients with
a long term follow-up and their relation with traditional
prognostic indicators and with the clinical outcome of the
patients was evaluated.
Materials and methods
Patient characteristics and tissue samples
Tissue specimens used for immunohistochemical analy-
ses were obtained from a series of consecutive, unselected
patients who had undergone curative surgery for colon
cancer at the Division of Surgery, Policlinico “Agostino
Gemelli”, School of Medicine, Università Cattolica del
Sacro Cuore, Rome, Italy, from June 2000 to December
2003 and for whom clinicopathological data were avai-
lable. A curative surgery was defined as one in which no
macroscopic tumour remained at the end of surgery and
in which histopathologic examination of the surgical spe-
cimen showed no tumour at the margins of resection. Dis-
tant metastases at the time of resection were excluded by
preoperative liver ultrasonography and/or CT scan, chest
X-ray and intraoperative exploration. After excluding
cases with previous personal and/or familiar tumour his-
tory and patients with multiple colon cancers and multiple
primary cancers or who received preoperative adjuvant
therapy or were lost to follow-up, a cohort of 137 patients
was selected for this study. Formalin fixed, paraffin em-
bedded specimens were retrieved for this study from the
archives of the Department of Pathology and two expe-
rienced pathologists (GFZ and MM) confirmed the his-
tological diagnosis of each lesion. Histological tumour
grading and staging were assessed according to standard
criteria [11]. Proximal colon was defined as the large bo-
wel proximal to the splenic flexure, and distal colon was
defined as the large bowel distal to the splenic flexure ex-
cluding rectum. Treatment remained reasonably consis-
tent during the study period.
Immuno peroxidase detection of CD133 and α-DG
Immunohistochemical analyses were performed on rou-
tinely processed, formalin-fixed, paraffin-embedded tissues
employing an avidin–biotin complex immunoperoxidasetechnique, as previously described [12,13]. A specific poly-
clonal anti-CD133 antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA; 1:100) was used for the stai-
ning. Comparable results but with a weaker staining
were obtained using the monoclonal AC133 antibody
(Miltenyi Biotec, Bergisch Gladbach, Germany; 1:10) (data
not shown). The monoclonal anti α-DG antibody (clone
VIA4-1) (Upstate Biotechnology, Lake Placid, NY) was
used at a concentration of 10 μg/ml in PBS with 1% horse
serum.
Controls for specificity of staining were performed by
immunostaining duplicate sections in the absence of the
primary antibody. Positive and negative control slides
were included within each batch of slides.
All scoring and interpretations of the results were
made by two of the authors independently (MM and LR)
without knowledge of other clinicopathological variables.
To assess interobserver variation, the results of the two
measurements were compared by paired t test and no
statistical differences were found (data not shown). The
few cases with discrepant scoring were re-evaluated jointly
on a second occasion, and agreement was reached.Statistical analysis
The association between molecular and clinic-patholo-
gical parameters were calculated using contingency table
methods and tested for significance using the Pearson’s
chi-square test. Patients were all uniformly followed-up at
our Institution and disease free survival (DFS) was defined
as the interval between surgery and the first documented
evidence of disease in local-regional area and/or distant
sites. Overall survival was defined as the interval between
surgery and death from the disease. Patients who died for
causes unrelated to disease were not included in the sur-
vival analyses. All calculations were performed using the
STATA statistical software package (Stata Corporation,
College Station, Texas) and the results were considered
statistically significant when the p value was ≤0.05.Results
Clinicopathological findings
The clinicopathological findings of the 137 patients are
listed in Table 1. The median age of the patients was
68 years (range, 31–86 years; mean, 66.8), and they in-
cluded 78 males (mean age 68.20± 10.10 ) and 59 females
(mean age 64.96 ± 12.60). According to TNM stage, 25
cases were stage I, 43 stage II and 69 stage III. Stage IV
patients were excluded from the analysis. The pathological
diagnosis was adenocarcinoma not otherwise specified
(NAS) in 122 cases and mucinous adenocarcinoma in the
remaining 15 cases. Based on grading, adenocarcinomas
were classified as well- or moderately differentiated in 95
cases, and poorly differentiated in 42 cases.
Table 1 Clinicopathological data
Age: 66.8 ±11.3 (mean age± SD, year)
Characteristics No. of patients (%)
Gender
Male 78 (56.9)
Female 59 (43.1)
Histotype
ADK NAS} 122 (89.1)
Mucinous 15 (10.9)
Tumour location
Proximal 60 (43.8)
Distal 77 (56.2)
Grading
Well 9 (6.6)
Modertae 86 (62.8)
Poor 42 (30.7)
TNM
T1 12 (8.8)
T2 17 (12.49
T3 101 (54.7)
T4 7 (24.1)
Nodal status
N0 76 (55.5)
N+ 61 (45.5)
Tumor stage
I 25 (18.2)
II 43 (31.4)
III 69 (50.4)
Recurrence
Yes 57 (41.6)
Not 80 (58.4)
Follow-up
Deceased 51 (37.2)
Alive 86 (62.8)
} ADK NAS: adenocarcinoma not otherwise specified.
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correlates with the clinical outcome of patients
CD133 expression was evaluated by immunostaining in
a series of 137 primary human colon cancers (Table 1)
and only a clear staining of the cell membrane and/or
cytoplasm was regarded as positive. Normal colonic mu-
cosa was present in about 50% of the cases and scattered
positive cells were rarely detected at the bases of the
crypts (Figure 1A and B).
In cancer cells the median percentage of positive cells
was 5% (range 0–80; mean=13%) and CD133 staining
was not detectable in tumour cells in 30 out of 137 (22%)
specimens (Figure 1C-F). When cases were stratifiedaccording with pT parameter, median percentage of posi-
tive cells was 17.5 (range 0–70; mean=24%), 10.0 (range
0–60; mean=16), 2.0 (range 0–65; mean=9) and 10
(range 0–80; mean= 13) in pT1, 2, 3 and 4 tumours, res-
pectively, and these differences were significant (p= 0.02).
Moreover, using the 5% positive cells as cut-off to distin-
guish between high (>5%) and low (≤5%) staining, high
CD133 staining was detected in 9 (75%) of the 12 pT 1
cancers and in 10 (59%), 27 (36%) and 19 (58%) of the pt2,
pT3 nd pT4 cancers, respectively and cross-tab analysis
identified a significant correlation (p= 0.02) between the
two parameters (Table 2). Significance was also evident
when earlier (pT1-2) tumours (66%) were compared toge-
ther vs more advanced (pT3-4) (42.6%) cancers (p= 0.02).
No correlation was observed with either tumour grade
and N status.
On the other hand, high CD133 staining was detected
in 16 (64%) of the 25 stage 1, 12 (28%) of the 43 stage II
and in 37 (54%) of the 69 more advanced stage 3 cancers
and cross-tab analysis identified a significant correlation
(p = 0.006) between the two parameters (Table 2). Signi-
ficance was no longer evident when stage 1/2 cancers
(41%) were compared overall with more advanced stage
3 cancers (54%) (p = 0.09) (Table 2).
When CD133 staining was analyzed in relation with
clinical outcome, both disease recurrence and disease-
related death were more frequent in patients whose tumor
expressed a high staining for CD133. Overall, median per-
centage of positive cells was 1.0 (range 0–80; mean=12.3
± 19.5%) and 10.0 (range 0–80; mean=13.9± 14.8%) in
non recurrent and recurrent cases, respectively, but this
difference was not significant. When tumours were strati-
fied according with CD133 expression, median DFS of
CD133 low expressor tumors was longer compared to
high expressor cases (80.5 ± 36.8 vs 48.0 ± 39.1 months)
and this difference was significant (p= 0.001). Moreover,
when tumours were stratified according with CD133 ex-
pression, twenty-two (30.6%) out of 72 low expressor cases
and 35 (54%) among the remaining 65 cases recurred du-
ring the period of follow-up and this difference was sig-
nificant (p= 0.005) as also confirmed by the Kaplan-Meier
curves of DFS which displayed a significant separation
between the two groups of patients (p= 0.002 by log-rank
test) (Figure 3A). Similarly, thirty-one (47.7%) out of
65 patients with high expresssor tumours and only 20
(27.8%) of the 72 remaining ones died of disease du-
ring the period of follow-up and this difference was
significant (p = 0.013) although median percentage of
positive cells was 2.0 (range 0–80; mean=13.6± 21.0%)
and 10.0 (range 0–40; mean=12.0± 10.0%) in alive and
death patients, respectively, and this difference was not
significant. Thus, patients with tumors displaying a higher
staining for CD133 were more likely to die for the disease
compared with low expressor tumors as confirmed by the
Figure 1 Examples of CD133 immunohistochemical staining in human colon samples. (A and B) Normal colonic mucosa. Note the rare (!)
positivity for CD133 (A, × 200 and B, × 400). (C) A early dysplastic lesion of colon tumorigenesis showing a marked positive immunostaining for
CD133 (× 200). (D) Example of a moderately differentiated NAS adenocarcinoma displaying a diffuse staining for CD133 (× 200). (E and F)
Examples of mucinous poorly differentiated adenocarcinomas displaying a strong and diffuse cytoplasmic staining for CD133 with a clear
immuno-negativity of nuclei (× 200 and × 550).
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ration between the two groups of patients (p= 0.008 by
log-rank test) (Figure 3B). Hence, increased expression of
CD133 was associated with an increased risk of recurrence
and death in our series of colon cancers (Figures 3A and B).
Loss of α-DG expression is a frequent event in colon
cancers and correlates with the clinical outcome of
patients
We previously reported that α-DG expression, as as-
sessed by western blot analysis, is frequently lost in hu-
man colon cancer cell lines and primary tumours and
correlates with tumour grade and stage. In this study, α-
DG expression level was assessed by immunostaining in
the same series of colon cancer samples using a specific
anti- α-DG antibody (Figure 2). An evident staining was
observed in the majority of normal specimens (Figure 2A
and B). In tumour tissues staining was highly heteroge-
neous in term of percent of positive cells with themedian percentage of positive cells being 30% (range
0–90; mean = 35%) (Figure 2C-F). DG levels did not
correlate with most of the analyzed parameters (age,
gender, pT parameter, tumour stage, grading, N status)
(Table 3). As previously mentioned, low DG expression
was also more frequent in tumours expressing increased
levels of CD133 (p= 0.006) (Table 2).
When DG staining was analyzed in relation with cli-
nical outcome, low DG expression was more frequent in
recurrent vs non-recurrent cases (p = 0.035) but the me-
dian percentage of positive cells was not different bet-
ween the two subgroups of patients. Finally, low DG
expression was also more frequent in deceased vs alive
patients (p = 0.014) and the median percentage of posi-
tive cells tended to be lower in deceased (median = 30.0;
range 0–80; mean= 31.1%) compared to surviving patients
(median= 40.0; range 0–90; mean=38.4%) (p= 0.07).
When tumours were stratified according with DG expres-
sion, mean DFS of DG low expressor tumors was shorter
Table 2 CD133 expression in relation to clinical and
pathological parameters in a series of 137 colon cancers
Total Low High p value
n (%) n (%)
Gender
Males 78 41 (53) 37 (47)
Females 59 31 (52) 28 (48) n.s.
Age (yr)
≤68 73 35 (48) 38 (52)
>68 64 37 (58) 27 (42) n.s.
Tumor Grading
1 9 4 (44) 5 (56)
2 86 50 (58) 36 (42)
3 42 18 (43) 24 (57) n.s.
pT parameter
pT1 12 3 (25) 9 (75)
pT2 17 7 (41) 10 (59)
pT3 75 48 (64) 27 (36)
pT4 33 14 ( 42) 19 (58) 0.02
Nodal status
Negative 76 42 (55) 34 (45)
Positive 61 30 (49) 31 (51) n.s.
Tumor stage
I 25 9 (36) 16 (64)
II 43 31 (72) 12 (28)
III 69 32 (46) 37 (54) 0.006
Recurrence
YES 57 22 (39) 35 (61)
NOT 80 50 (62) 30 (37) 0.005
Follow-up
Deceased 51 20 (39) 31 (61)
Alive 86 52 (61) 34 (39) 0.013
α-DG staining
Low 68 28 (41) 40 (59)
High 69 44 (64) 25 (36) 0.006
n.s.: not significant.
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and this difference was significant (p= 0.035) as also con-
firmed by the Kaplan-Meier curves of DFS which dis-
played a significant separation between the two groups of
patients (p= 0.02 by log-rank test) (Figure 3C). Similarly,
mean OS of DG low expressor tumors was shorter com-
pared to high expressor cases (72.6 vs 91.8 months) and
this difference was significant (p= 0.025) as also confirmed
by the Kaplan-Meier curves of OS which displayed a sig-
nificant separation between the two groups of patients
(p= 0.01 by log-rank test) (Figure 3D).CD133 immunostaining is an independent prognostic
parameter in colon cancer patients
To further explore the prognostic significance of CD133
and α-DG, we built a Cox regression model including
the two parameters with tumour grade, pT and N para-
meters. Only a high CD133 staining (p=0.002; C.I. 1.365-
4.171; RR=2.4) and lymph node involvement (p=0.001;
CI = 1.532-5.876; RR=3.0) confirmed to be independent
predictors of shorter disease-free survival (Table 4). It
is noteworthy that α-DG confirmed to be an indepen-
dent prognostic indicator when CD133 was not inclu-
ded in the model (p=0.024; C.I. 1.086-3.144; RR= 1.8), a
result expected given the correlation between the two
parameters.
A similar Cox regression model including also the age
confirmed the independent prognostic significance of only
CD133 staining (p=0.003; C.I. 1.332-4.114; RR= 2.3) and
lymph node involvement (p=0.001; CI = 1.546-5.911; RR=
3.0) also in term of overall survival (Table 5). α-DG stai-
ning did not display an independent prognostic signifi-
cance also when CD133 was not included in the model
(p=0.051; C.I. 0.997-2.902; RR=1.7).
Discussion
In this study, the expression of the surface markers
CD133 and α-DG was evaluated in a subset of colon
cancers and their potential prognostic significance was
investigated.
We and others previously reported that loss of the α
subunit of the DG complex (α-DG) is a frequent event
in human cancers [6,8,10,12,14-16]. We also demons-
trated, by western blot analysis, that α-DG is frequently
reduced in colon cancer tissues compared to normal ad-
jacent normal tissues while the β subunit did not display
significant variations between normal and tumour tis-
sues [12]. In this study, we further analyzed the DG in-
volvement in colon tumorigenesis and confirmed, by
immunohistochemistry, that detection of α-DG is fre-
quently reduced or lost in the majority of cancer tissues
compared to adjacent normal tissues (Figure 2) and that
loss of α-DG correlates with a worse prognosis (Figure 3).
These findings are in agreement with the proposed tu-
mour-suppressor function of the protein [17] and with
previous observations in several human malignancies
[5,18-20]. The functional inactivation of the DG complex
in tumour cells has been mainly attributed to post-trans-
lation mechanisms which cause the loss and/or an al-
tered glycosylation of the extracellular α-DG [21-25].
Since DG subunits are encoded by a single gene and are
formed upon cleavage of a precursor protein [6,26], our
previous findings that β-DG subunit is detectable in
most of the colon cancers in which α-DG was not de-
tectable [12] suggest that, as reported in other types of
human malignancies, this lack of detection is likely not
Figure 2 Examples of α-DG immunohistochemical staining in human colon samples. (A) Normal colonic mucosa. Note the intense
cytoplasmic immunopositivity of caliciform cells of the cryptes (× 20) and the positive staining of the stroma likely due its muscolar fraction,
which served as positive control. (B) Normal colonic mucosa. Note the strongest staining on the basis of cells and the reinforcement of basal
membrane (arrows) (× 40. (C) A well differentiated NAS adenocarcinoma displaying a diffuse staining for α-DG (× 200). (D) A poorly differentiated
NAS adenocarcinoma displaying an intense cytoplasmic staining for α-DG (× 400). (E and F) A mucinous poorly differentiated adenocarcinoma
displaying a clear diffuse cytoplasmic staining for α-DG (× 200 and × 550).
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criptional mechanism affecting α-DG processing in colon
cancer cells.
The DG complex connects the ECM network to the
cytoskeleton and is likely involved in the regulation of
signaling pathways [6]. Thus, regardless of the under-
lying molecular mechanisms, loss of a functional α-DG
subunit can play an important role in the tumorigenesis
process by compromising the formation of strong con-
tacts between ECM and the cytoskeleton of cells resul-
ting, as for integrins, in less sticky tumour cells able to
move unhindered in the extracellular matrix, thus predis-
posed to invade surrounding tissue and metastasize [6,17].
It will be of interest to evaluate DG expression in the en-
tire process of human colon tumorigenesis (i.e., from early
to metastatic lesions).
CD133 has been reported to be a CSC marker in colo-
rectal cancer [27,28], and, although some doubts havebeen arisen about its ability to specifically identify tu-
mour-initiating cells [29], it has been widely used to
identify and analyze CSC in colorectal cancers. We were
able to detect CD133 staining in the majority (78%) of
colon cancers analyzed although with a high heteroge-
neity in term of percentage of positive cells (range 0-80%)
whose increase was associated with an increased risk
of recurrence and death for the disease (Table 2 and
Figure 3). These findings are in agreement with previous
evidence suggesting a potential prognostic role of the pro-
tein in colon cancer patients. Indeed, it has been reported
that CD133 expression levels correlate with patients sur-
vival in colorectal cancers [1-3,30,31] although available
data on the presence of CD133+ cells in human colorectal
cancers are not always consistent in term of distribution
and percentage of positive cells. Several factors might ex-
plain such discrepancies: i) inadequate patient cohort; ii)
mixed tumour stages; iii) different criteria used to identify
Figure 3 Kaplan-Meier curves for disease-free (upper panels) and overall (lower panels) survival in a series of 137 colorectal cancer
patients. Patients were stratified by CD133 expression (A, B) or according to the level of α-DG expression (C, D) (see text for details).
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positive and negative tumours; v) different antibodies used
for the analysis, with the latter being, in our opinion, the
most important factor. Different antibodies have been in-
differently used in different studies for the detection of the
CD133 molecule. In our opinion this can be a highly con-
fusing factor. Indeed, we previously demonstrated, by
western blot analysis, that CD133 is expressed at various
levels in colon cancers [32,33] and that different results
can be obtained by using different antibodies [34] and
similar observations have been also reported by other
Authors [35,36]. The observation that high CD133 expres-
sion has been reported to be a negative prognostic factor
for colorectal cancers in several studies using different
antibodies strongly suggests an important prognostic sig-
nificance of its detection [1,2,37]. In our study, CD133 also
confirmed to be an independent risk factor for a shorter
disease-free and overall survival in a multivariate analysis
(Tables 4 and 5). These findings are consistent with simi-
lar results reported in other human cancers and warrant
studies on larger cohorts of patients to further evaluate its
suitability as a prognostic marker in the clinical manage-
ment of colon cancer patients.We observed an unexpected behaviour of CD133 ex-
pression which tended to be higher in the lowest grade/
stage tumours than in more advanced lesions. Although
not expected, this distribution is consistent with pre-
vious findings in a mouse model of colon carcinogenesis
[38] and in human primary colon cancers [39]. Indeed, in
mouse colon carcinogenesis we observed a significantly
increased expression of CD133, assessed by immunohisto-
chemistry, in early neoplastic lesions which tended to de-
crease with tumour development, although remaining
always higher in cancer than in normal adjacent tissues
[38] and an increased CD133 expression, assessed using a
quantitative reverse-transcription PCR, was reported in
Dukes A compared to Dukes B and C colon cancers [39].
These findings are in agreement with the proposed ability
of the protein to specifically identify tumour initiating
cells, important for the growth of both primary and recur-
rent/metastatic cancers [40] and thus mainly involved in
the most active phases of tumour development, i.e., in
early lesions (low grade and low stage cancers) as well as
in metastatic lesions. Consistent with this hypothesis,
CD133 expression has been reported to be highly ex-
pressed in colon cancers with early liver metastases and to
Table 3 α-DG expression in relation to clinical and
pathological parameters in a series of 137 colon cancers
Total Low High p value
n (%) n (%)
Gender
Males 78 42 (54) 36 (46)
Females 59 26 (44) 33 (56) n.s.
Age (yr)
≤68 73 33 (45) 40 (55)
>68 64 34 (54) 29 (46) n.s.
Tumor Grading
1 9 3 (33) 6 (67)
2 86 45 (52) 41 (48)
3 42 20 (48) 22 (52) n.s.
pT parameter
pT1 12 7 (58) 5 (42)
pT2 17 7 (41) 10 (59)
pT3 75 35 (47) 40 (53)
pT4 33 19 (58) 14 (42) n.s.
Nodal status
Negative 76 37 (49) 39 (51)
Positive 61 31 (51) 30 (49) n.s.
Tumor stage
I 25 11 (44) 14 (56)
II 43 18 (42) 25 (58)
III 69 39 (56) 30 (44) n.s.
Recurrence
YES 57 34 (60) 23 (40)
NOT 80 34 (42) 46 (58) 0.035
Follow-up
Deceased 51 32 (63) 19 (37)
Alive 86 36 (42) 50 (58) 0.014
n.s.: not significant.
Table 4 Contribution of various potential prognostic
factors to disease free survival by Cox regression analysis
in colon cancer patients
Hazard 95% confidence
Variable ratio interval p value
Tumor grade* 1.438 0.801-2.583 0.223
pT parameter# 2.027 0.806-5.094 0.133
Node status** 3.000 1.532-5.876 0.001
CD133} 2.386 1.365-4.171 0.002
Dystroglycan}} 1.629 0.950-2.794 0.076
The risk ratio is given as: * higher (G3) versus lower grade (G1/2); # higher
(pT3/4) versus lower (pT1/2) pT parameter; ** node-positive vs node-negative;
} positive vs negative and }} negative vs positive.
Table 5 Contribution of various potential prognostic
factors to overall survival by Cox regression analysis in
colon cancer patients
Hazard 95% confidence
Variable ratio interval p value
Age° 1.431 0.842-2.432 0.185
Tumor grade* 1.380 0.767-2.484 0.282
pT parameter# 1.850 0.744-4.599 0.185
Node status** 3.023 1.546-5.911 0.001
CD133} 2.341 1.332-4.114 0.003
Dystroglycan}} 1.462 0.845-2.532 0.175
The risk ratio is given as: ° older (>68 y) versus younger patients; * higher (G3)
versus lower grade (G1/2); # higher (pT3/4) versus lower (pT1/2) pT parameter;
** node-positive vs node-negative; } positive vs negative and }} negative vs
positive.
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and we also previously reported an increased percentage
of CD133+ cells, assessed by flow cytometry, in metastatic
vs primary colon cancers, [42]. It will be of interest to eva-
luate the immunohistochemical CD133 expression in the
entire process of human colon tumorigenesis (i.e., from
early to metastatic lesions) and evaluate how it correlates
with tumour development.
An unexpected finding of the present study was the
observed inverse relationship between CD133 and α-DG
expression (Table 2). The significance of this observation
is unknown since no data are available up to date linking
the two molecules. It is of interest that DG expression
increases with cell differentiation while CD133 expression
decreases in differentiated cells [7,33,43-45] thus sugges-
ting a potential functional link between the two molecules.
Further studies will be required to fully understand the
biological significance of the observed relationship bet-
ween the two molecules.
Conclusions
To our knowledge, this is the first study analyzing the
immunohistochemical expression of both CD133 and α-
DG, two surface molecules previously reported to be
altered in human colorectal cancers, in a large series of
colon cancer patients. Our results demonstrate that an
inverse relationship exists between the two molecules
(Table 2) and that CD133 expression is an independent
risk factor associated with patient survival in multivari-
ate analyses (Tables 4 and 5). The role of CD133 as a
biomarker for CSC is still debated [46]. Regardless of its
significance as a CSC marker, however, our results sug-
gest that evaluation of CD133 staining might be useful
to identify colon cancer patients at high risk of recurrence
and death. Thus, we believe, as previously reported, that it
will be important to define standardized procedures and
reagents to evaluate expression of this molecule in cli-
nical samples [34. Afterwards, a prospective multicenter
Coco et al. Journal of Experimental & Clinical Cancer Research 2012, 31:71 Page 9 of 10
http://www.jeccr.com/content/31/1/71evaluation of CD133 immunostaining on a larger popula-
tion of surgically resected colon cancers is warranted to
allow a conclusive and definitive assessment of its suitabi-
lity in predicting tumor aggressiveness and outcome in
colon cancer patients.
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